Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EBIT: 2021-2025

Historic EBIT for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Sep 2025 value amounting to $8.5 million.

  • Arcutis Biotherapeutics' EBIT rose 121.82% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.2 million, marking a year-over-year increase of 78.98%. This contributed to the annual value of -$128.4 million for FY2024, which is 46.75% up from last year.
  • Arcutis Biotherapeutics' EBIT amounted to $8.5 million in Q3 2025, which was up 158.35% from -$14.6 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' EBIT's 5-year high stood at $8.5 million during Q3 2025, with a 5-year trough of -$104.7 million in Q3 2022.
  • Its 3-year average for EBIT is -$36.4 million, with a median of -$36.9 million in 2023.
  • Per our database at Business Quant, Arcutis Biotherapeutics' EBIT plummeted by 83.52% in 2022 and then soared by 121.82% in 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' EBIT (Quarterly) stood at -$71.3 million in 2021, then rose by 4.01% to -$68.4 million in 2022, then rose by 10.60% to -$61.2 million in 2023, then spiked by 87.52% to -$7.6 million in 2024, then surged by 121.82% to $8.5 million in 2025.
  • Its EBIT was $8.5 million in Q3 2025, compared to -$14.6 million in Q2 2025 and -$24.5 million in Q1 2025.